Merck & Co (NYSE: MRK) has published updated findings from its Keynote-012 trials for its head and neck cancer drug Keytruda (pembrolizumab) at the American Society of Clinical Oncologists (ASCO) 2016 conference.
The trial showed continued benefit in response rates and duration of response lasting up to 30 months in patients with previously treated recurrent or metastatic head and neck cancer recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
In Keynote-012, for the primary endpoint, findings showed an overall response rate (ORR) of 18%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze